Compare Lennar Corporation (LEN) vs Nuvation Bio Inc. Class A Common Stock (NUVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lennar Corporation vs Nuvation Bio Inc. Class A Common Stock — how do they compare? Lennar Corporation trades at $76.62 (market cap $18.44B), while Nuvation Bio Inc. Class A Common Stock trades at $4.99 (market cap $1.74B). The key difference: Lennar Corporation is far larger — about 10.6× Nuvation Bio Inc. Class A Common Stock's market cap, and Lennar Corporation pays a 2.58% dividend while Nuvation Bio Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lennar Corporation for 67 Days and Nuvation Bio Inc. Class A Common Stock for 1 Days on average.
| LEN | NUVB | |
|---|---|---|
Market Cap | $18.44B | $1.74B |
Volume | 6,012,214 | 9,289,619 |
Sector | Consumer Cyclical | Health |
52-Week High | $133.13 | $9.54 |
52-Week Low | $74.44 | $3.41 |
Typical Hold Time | 67 Days | 1 Days |
Enterprise Value | $22.86B | $1.33B |
Dividend Yield | 2.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lennar (LEN) trades at $76.04, down 0.12% with bearish technical signals and recent earnings misses. The stock shows attractive valuation metrics with P/E of 14.7 and P/B of 0.86, but faces declining profitability with net margin dropping to 4.09% in 2025. Berkshire Hathaway's significant stake accumulation contrasts with Morgan Stanley's sell rating, highlighting divergent views on the housing market recovery timeline.
The investment case balances deep value against cyclical headwinds. While trading below book value and showing institutional confidence from Berkshire, Lennar faces mortgage rate pressures and earnings volatility. The consensus price target of $77.38 suggests limited upside, requiring careful monitoring of housing market conditions and execution on the asset-light strategy.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →
